Skip to main content

Antoni Ribas, M.D., Ph.D., SU2C-CRI Cancer Immunology Dream Team InvestigatorUniversity of California, Los Angeles

If we can merge the high response rate and the elegance of targeted therapy with the durability of responses from immunotherapy, I feel we will make a big difference in treating cancer.
Area of Research: Prostate Cancer, Kidney Cancer, Melanoma, Lung Cancer, All Cancers

Dr. Ribas, along with James P. Allison, Ph.D., Drew M. Pardoll, M.D., Ph.D., and Cassian Yee, M.D., is leading the SU2C-CRI Cancer Immunology Translational Research Dream Team, which is performing comprehensive experiments aimed at improving immunotherapy’s ability to improve patient outcomes.

Among the Dream Team’s activities are: systematically assessing the expression of candidate molecules and pathways in the tumor microenvironment before and after checkpoint blockade immunotherapy; using a combination of sequencing techniques to assess checkpoint blockade-induced T-cell responses to tumor-specific neo-antigens; working to improve the quality of cancer-specific T cell generated for adoptive cell transfer (ACT) therapy; evaluating the effect of epigenetic therapy on immunotherapy and assessing the combination of checkpoint blockade immunotherapy and ACT in patients.

Dr. Ribas is the 2018 recipient of the AACR-CRI Lloyd J. Old Award in Cancer Immunology. 

Projects and Grants

Immunologic checkpoint blockade and adoptive cell transfer in cancer therapy

University of California, Los Angeles | All Cancers, Kidney Cancer, Lung Cancer, Melanoma, Prostate Cancer | 2013

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top